ASTH

Analyst Rating and Price Target: Truist Financial analyst Jailendra Singh has maintained a Buy rating on Astrana Health (ASTH) with a price target of $46.00, while the stock closed at $31.38 last Thursday.

Market Consensus: The overall analyst consensus for Astrana Health is a Strong Buy, with an average price target of $48.13, despite Singh's personal average return being -16.3% and a success rate of 33.05%.

Earnings Release Announcement: Astrana Health, Inc. will release its financial results for the first quarter of 2025 on May 8, 2025, followed by a conference call at 2:30 p.m. PT to discuss the results.

Company Overview: Astrana Health is a technology-driven healthcare company that supports over 12,000 providers and 1.1 million Americans in value-based care arrangements, focusing on delivering high-quality and cost-effective healthcare.

Medicare Payment Update: The U.S. Centers for Medicare & Medicaid Services announced a 5.06% increase in payments to Medicare Advantage plans for 2026, significantly higher than previous estimates due to updated spending data from traditional Medicare.

Impact on Healthcare Companies: Analysts view the rate update positively for Medicare Advantage, predicting benefits for companies like Alignment Healthcare and Agilon Health, as well as broader implications for value-based care organizations.

Analyst Ratings Overview: Astrana Health has received mixed analyst ratings over the past quarter, with 4 bullish, 1 somewhat bullish, and 1 indifferent rating, while recent price targets have decreased significantly from an average of $64.00 to $47.83.

Company Performance Insights: Despite a notable revenue growth rate of approximately 88.43%, Astrana Health struggles with profitability as indicated by below-average net margins, return on equity, and return on assets, alongside a prudent debt management strategy.

Put Selling and Risks: Selling a put option on Astrana Health Inc does not provide the same upside potential as owning shares, as the seller only benefits from the premium unless the stock price drops significantly and the contract is exercised.

Market Activity: Recent trading data shows an increased put volume among S&P 500 components, indicating more put buyers than expected, with a put:call ratio of 0.75 compared to the long-term median of 0.65.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Price Target Adjustment: Baird has reduced the price target for Astrana Health (ASTH) from $86 to $50 while maintaining an Outperform rating on the shares.

Recent Company Developments: Astrana Health has reported strong revenue growth for 2024, received a buy recommendation despite temporary AI-related costs, and has delayed its yearly report filing.

Diagnostics Sector Performance: Diagnostics shares fell by approximately 2.1%, with Astrana Health and DocGo experiencing significant declines of 32.2% and 24.6%, respectively.

Market Commentary: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.

Quarterly Performance: Astrana Health, Inc. reported a quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of $0.09, while revenues reached $665.21 million, exceeding expectations by 5.42%.

Future Outlook: The company's earnings outlook is currently unfavorable, reflected in a Zacks Rank #4 (Sell), indicating potential underperformance in the near future despite outperforming the market so far this year.

Company Performance Overview: Astrana Health, Inc. reported a significant increase in total revenue for 2024, reaching $2.03 billion, up 47% from the previous year, despite a net income decline to $43.1 million compared to $60.7 million in 2023. The company aims to continue its growth and improve care quality while managing costs effectively.

Future Outlook and Guidance: Looking ahead, Astrana expects total revenue for 2025 to range between $2.5 billion and $2.7 billion, with Adjusted EBITDA projected between $170 million and $190 million, factoring in strategic investments and integration costs related to acquisitions.

Upcoming Investor Conferences: Astrana Health, Inc. CEO Brandon Sim will participate in several investor conferences in March 2025, including discussions on value-based care and technology in healthcare.

Company Overview: Astrana Health is a technology-driven healthcare company based in Alhambra, California, serving over 12,000 providers and 1.1 million Americans through integrated value-based care solutions.

Analyst Ratings on Healthcare Stocks: Analysts have expressed bullish sentiments towards Trevi Therapeutics, Astrana Health, and Penumbra, with all three companies receiving "Strong Buy" ratings and significant price targets indicating potential upside.

Price Targets and Analyst Performance: Trevi Therapeutics has a target of $12.00, Astrana Health at $56.00, and Penumbra at $301.00, with analysts from Stifel Nicolaus showing strong performance metrics in the healthcare sector.

Financial Results Announcement: Astrana Health, Inc. will release its financial results for the fourth quarter and full year ending December 31, 2024, on February 27, 2025, followed by a conference call at 2:30 PM PT/5:30 PM ET.

Company Overview: Astrana Health is a technology-driven healthcare company based in Alhambra, California, serving over 12,000 providers and 1.1 million Americans through value-based care arrangements.

Earnings Performance: Encompass Health (EHC) reported quarterly earnings of $1.17 per share, exceeding estimates and showing a year-over-year increase from $0.95. The company also achieved revenues of $1.41 billion, surpassing expectations and marking a significant rise from the previous year's $1.25 billion.

Future Outlook: Despite recent strong performance, the earnings outlook for Encompass Health is currently unfavorable, resulting in a Zacks Rank #4 (Sell). Investors are advised to monitor upcoming earnings estimate revisions as they could influence stock performance moving forward.

Share Repurchase Announcement: Astrana Health, Inc. announced the repurchase of 300,000 shares of its common stock for $10.551 million, reflecting management's confidence in the company's performance and commitment to long-term growth.

Company Overview: Astrana Health is a technology-driven healthcare company that supports providers in delivering high-quality, accessible care, serving over 12,000 providers and 1.1 million Americans through value-based care arrangements.

Financial Struggles of Prospect Medical Holdings: Prospect Medical Holdings is seeking restructuring advice to tackle ongoing financial difficulties, including missed rent payments to its landlord, Medical Properties Trust.

Regulatory Pressure and Facility Conditions: The hospital chain, operating in multiple states, is facing scrutiny from regulators due to its financial issues and the declining conditions at its healthcare facilities.

Company Announcement: Astrana Health, Inc. will participate in the J.P. Morgan 2025 Healthcare Conference on January 14, 2024, with a presentation by President and CEO Brandon Sim at 10:30 am PT.

About Astrana Health: The company is a technology-driven healthcare provider that supports over 12,000 providers and 1.1 million Americans in value-based care arrangements, focusing on delivering high-quality, accessible healthcare.

Stock Performance Overview: ASTH's stock has a 52-week low of $29.625 and a high of $63.20, with the last trade recorded at $44.51.

Market Insights: The article suggests checking for other stocks that have recently fallen below their 200-day moving average.

Astrana Health Inc Trading Update: Shares of Astrana Health Inc (ASTH) have entered oversold territory with an RSI reading of 28.8, indicating potential buying opportunities as the stock has experienced significant selling pressure.

Stock Performance Overview: ASTH's current trading price is $44.29, within a 52-week range of $29.625 to $63.20, suggesting volatility and possible recovery prospects for investors.

Acquisition Announcement: Astrana Health, Inc. has entered into a definitive agreement to acquire Prospect Health for $745 million, which includes various healthcare services and assets across multiple states, enhancing its provider network and patient care capabilities.

Strategic Goals: The acquisition aims to expand access to high-quality, patient-centered care for approximately 1.7 million members, with plans for significant investments in Prospect's infrastructure to improve local healthcare delivery.